<DOC>
	<DOCNO>NCT00290056</DOCNO>
	<brief_summary>We hypothesize oral supplementation omega-3 PUFA decrease occurrence arrhythmic event among post-MI , ICD recipient .</brief_summary>
	<brief_title>Effect Supplemental Intake Omega-3 Polyunsaturated Fatty Acids Rate Complexity Spontaneously Occurring Ventricular Supraventricular Arrhythmias Patients With Implantable Cardioverter Defibrillator ( ICD ) - A Randomized Clinical Trial</brief_title>
	<detailed_description>This randomize , placebo-controlled , crossover , double- blind interventional study . Patients receive 3.6 g EPA DHA fish oil placebo oil 6 month , randomly , crossover design , four month washout period treatment . Randomization stratify ejection fraction ( â‰¤ 35 % &gt; 35 % ) , type index arrhythmia ( VT - spontaneous inducible electrophysiologic study ( EPS ) , versus - VF , SCD , Primary prevention - MADIT II ) . Ischemia severity chosen evaluate Single Photon Emission Computed Tomography ( SPECT ) stress ( dipyridamol infusion ) . Subcutaneous adipose-tissue biopsy , biomarker consider gold-standard objective assessment long-term habitual dietary intake fish marine omega-3 PUFA ( EPA DHA ) obtain . Compliance monitor counting return capsule bottle measure omega-3 PUFA composition red blood cell ( RBC ) . Three different type questionnaire use trial obtain information additional potential benefit omega-3 PUFA supplementation : 1 . The newly Israeli Food Frequency Questionnaire ( FFQ ) use examine dietary intake nutritional habits/patterns relationship study outcome . 2 . The Hebrew language SF-36 health survey use examine general health status . 3 . The Back questionnaire use examine possible beneficial effect fish oil supplementation depressive symptomatology .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>postMI patient . Both single Dual chamber ICD recipient . implanted 3 month ago . Agree give write informed consent . Less 18 year age . ICD implantation ` bridge ` heart transplantation . Stable antiarrhythmic medication last month prior enrollment . Patients take class I antiarrhythmic medication . A projected lifespan less one year . Participation another trial ( within 90 day study ) . Use supplemental n3 fatty acid last 3 month . Women pregnant childbearing potential use adequate contraception . Patients known history recent drug alcohol abuse . 10 ) History current intestinal hepatic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>CHD</keyword>
	<keyword>Arrhythmia</keyword>
	<keyword>ICD</keyword>
	<keyword>Omega-3 PUFA</keyword>
	<keyword>Nutrition</keyword>
</DOC>